As of 2024-12-14, the Intrinsic Value of Kiniksa Pharmaceuticals Ltd (KNSA) is (10.41) USD. This KNSA valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 20.20 USD, the upside of Kiniksa Pharmaceuticals Ltd is -151.50%.
The range of the Intrinsic Value is (29.75) - (6.20) USD
Note: result may not be accurate due to the invalid valuation result of DCF model.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (29.75) - (6.20) | (10.41) | -151.5% |
| DCF (Growth 10y) | (4.87) - (20.67) | (7.72) | -138.2% |
| Fair Value | -1.74 - -1.74 | -1.74 | -108.63% |
| P/E | (4.18) - (6.27) | (5.22) | -125.9% |
| EPV | (3.26) - (5.02) | (4.14) | -120.5% |
| DDM - Stable | (0.84) - (3.03) | (1.93) | -109.6% |
| DDM - Multi | (0.77) - (2.23) | (1.15) | -105.7% |
| Market Cap (mil) | 1,458.44 |
| Beta | 1.11 |
| Outstanding shares (mil) | 72.20 |
| Enterprise Value (mil) | 1,361.06 |
| Market risk premium | 4.60% |
| Cost of Equity | 11.13% |
| Cost of Debt | 5.00% |
| WACC | 7.40% |